These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37247021)

  • 1. Magnetic resonance imaging-derived parameters to predict response to regorafenib in recurrent glioblastoma.
    Martucci M; Ferranti AM; Schimperna F; Infante A; Magnani F; Olivi A; D'Alessandris QG; Gessi M; Chiesa S; Mazzarella C; Russo R; Giordano C; Gaudino S
    Neuroradiology; 2023 Oct; 65(10):1439-1445. PubMed ID: 37247021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/MR in recurrent glioblastoma patients treated with regorafenib: [
    Lombardi G; Spimpolo A; Berti S; Campi C; Anglani MG; Simeone R; Evangelista L; Causin F; Zorzi G; Gorgoni G; Caccese M; Padovan M; Zagonel V; Cecchin D
    Br J Radiol; 2022 Jan; 95(1129):20211018. PubMed ID: 34762492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
    Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
    Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH genotypes differentiation in glioblastomas using DWI and DSC-PWI in the enhancing and peri-enhancing region.
    Xing Z; Zhang H; She D; Lin Y; Zhou X; Zeng Z; Cao D
    Acta Radiol; 2019 Dec; 60(12):1663-1672. PubMed ID: 31084193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
    Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
    Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.
    Rahman R; Hamdan A; Zweifler R; Jiang H; Norden AD; Reardon DA; Mukundan S; Wen PY; Huang RY
    J Neurooncol; 2014 Aug; 119(1):149-58. PubMed ID: 24805151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
    Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
    Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.
    Auer TA; Breit HC; Marini F; Renovanz M; Ringel F; Sommer CJ; Brockmann MA; Tanyildizi Y
    J Neuroradiol; 2019 Feb; 46(1):36-43. PubMed ID: 29733920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinguishing Tumor Recurrence From Radiation Necrosis in Treated Glioblastoma Using Multiparametric MRI.
    Feng A; Yuan P; Huang T; Li L; Lyu J
    Acad Radiol; 2022 Sep; 29(9):1320-1331. PubMed ID: 34896001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.
    Hagiwara A; Oughourlian TC; Cho NS; Schlossman J; Wang C; Yao J; Raymond C; Everson R; Patel K; Mareninov S; Rodriguez FJ; Salamon N; Pope WB; Nghiemphu PL; Liau LM; Prins RM; Cloughesy TF; Ellingson BM
    Neuro Oncol; 2022 Jun; 24(6):1020-1028. PubMed ID: 34865129
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Choi HJ; Choi SH; You SH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park CK; Park SH
    AJNR Am J Neuroradiol; 2021 May; 42(5):853-860. PubMed ID: 33632732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apparent Diffusion Coefficient as a Predictive Biomarker for Survival in Patients with Treatment-Naive Glioblastoma Using Quantitative Multiparametric Magnetic Resonance Profiling.
    Kim BS; Kim ST; Kim JH; Seol HJ; Nam DH; Shin HJ; Lee JI; Kong DS
    World Neurosurg; 2019 Feb; 122():e812-e820. PubMed ID: 30391622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation of brain infection from necrotic glioblastoma using combined analysis of diffusion and perfusion MRI.
    Chawla S; Wang S; Mohan S; Nasrallah M; Verma G; Brem S; O'Rourke DM; Wolf RL; Poptani H; Nabavizadeh SA
    J Magn Reson Imaging; 2019 Jan; 49(1):184-194. PubMed ID: 29676844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging.
    Yang X; Xing Z; She D; Lin Y; Zhang H; Su Y; Cao D
    BMC Med Imaging; 2022 May; 22(1):105. PubMed ID: 35644621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab.
    Chang K; Zhang B; Guo X; Zong M; Rahman R; Sanchez D; Winder N; Reardon DA; Zhao B; Wen PY; Huang RY
    Neuro Oncol; 2016 Dec; 18(12):1680-1687. PubMed ID: 27257279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI.
    Saini J; Kumar Gupta P; Awasthi A; Pandey CM; Singh A; Patir R; Ahlawat S; Sadashiva N; Mahadevan A; Kumar Gupta R
    Clin Radiol; 2018 Nov; 73(11):986.e7-986.e15. PubMed ID: 30197047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
    Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.